FGFR3 Antagonist for Skeletal Disorders Treatment
Summary
The USPTO published patent application US20260091033A1 for an FGFR3 antagonist for treating skeletal disorders linked to abnormal FGFR3 activation. The application, filed by inventors LEGEAI-MALLET, MUNNICH, BUSCA, and BARBAULT on January 15, 2025, covers compositions and methods for treatment. This publication represents a new patent application and creates no immediate compliance obligations for industry.
What changed
The USPTO published a patent application for an FGFR3 (fibroblast growth factor receptor 3) antagonist composition for use in treating or preventing skeletal disorders associated with abnormal FGFR3 activation. The application (No. 19021632) covers pharmaceutical compositions, methods of treatment, and uses of the antagonist for conditions including achondroplasia and other FGFR3-related skeletal dysplasias. Named inventors include Laurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, and Florent BARBAULT. \n\nPatent applications do not create compliance obligations. Pharmaceutical companies and researchers developing FGFR3-targeted therapies should monitor this application through the USPTO prosecution process. No action is required at this time—this document is informational, marking the publication of a pending application rather than a granted patent or regulatory requirement.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3
Application US20260091033A1 Kind: A1 Apr 02, 2026
Inventors
Laurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, Florent BARBAULT
Abstract
The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
CPC Classifications
A61K 31/506 A61K 31/519 A61K 38/177 A61K 38/179 B29C 48/0017 B29C 48/022 B32B 27/302 C08J 5/18 C08L 25/06 C08L 51/04 B29K 2025/06 B29K 2035/00 B29K 2201/00 B29L 2031/712 B32B 2262/06 B32B 2270/00 B32B 2439/70 C08J 2325/06 C08J 2401/00 C08J 2401/02 C08J 2425/06 C08J 2425/08 C08J 2447/00 C08L 2203/30 C08L 2205/02 C08L 2205/025 C08L 2205/03 C08L 2205/035 C08L 2205/16
Filing Date
2025-01-15
Application No.
19021632
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.